Tarsus Pharmaceuticals Acquires iRenix Medical, Developer of Late-Stage Ocular Antiseptic IRX-101

IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company focused on therapeutic eyecare, has announced the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic biopharmaceutical company and developer of IRX-101, an investigational ocular antiseptic with the potential to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy. The companies disclosed that the financial transaction included an upfront consideration of approximately $75 million, consisting of $37.5 million in cash and $37.5 million in Tarsus common stock, with potential approval and commercial milestone payments of up to $490 million.